D3 Bio, a JiangSu and Shanghai, China-based biotechnology company, received $40M in Investment from Medicxi.
The company intends to use the funds to accelerate the development of its pipeline of oncology compounds.
Lee by CEO George Chen, D3 Bio is a clinical stage biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology. It has built a pipeline of multiple oncology assets, all with potential and foundational properties targeting immune-pathways or tumor driving mutations. Three compounds have already entered clinical trials, including:
- D3S-001 is a new generation small molecule KRAS G12C inhibitor with differentiated properties and could potentially address the still large unmet need of patients with cancers harboring KRAS G12C mutations. D3S-001 is currently in phase II development in non-small cell lung cancer, colorectal cancer and pancreatic cancer.
- D3S-002 is a distinctively designed, novel small molecule ERK1/2 kinase inhibitor with promising activity, selectivity, and favorable safety profile in preclinical assessments. The combination of D3S-002 and D3S-001 has demonstrated promising and synergistic antitumor activity in preclinical models. D3S-002 is being tested in an ongoing phase I trial.
- D3L-001, currently in Phase I development is a novel HER2×CD47 bi-specific antibody which has demonstrated potent and synergistic anti-tumor effect via HER2 guided CD47 co-blocking in both in vitro and in vivo models.
Commenting on the news, George Chen said: “Medicxi’s longstanding success has been built on its uniquely strong ties to pharmaceutical companies and its extensive team of world class subject matter experts, drug hunters and developers who act as partners for the innovators in which they are investing. Their expertise and knowledge will be instrumental in accelerating our mission to advance breakthroughs in cancer treatment to transform the lives of patients across the globe. With Medicxi’s leadinvestment and participations from existing investors, D3 Bio successfully closed its Series A+ financing round.”
FinSMEs
08/04/2024